Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 2/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 5/20 | 0.38 |
| ▸ | VEGFA | P15692 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23842815 | 0.81 | SLC6A4 (0.40) | SLC6A2SLC6A4SLC6A3MGLLEPAS1 | |
| SCHEMBL28014799 | 0.80 | EPHX2 (0.42) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9913868 | 0.77 | FFAR4 (0.44) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL932285 | 0.75 | KMT2A (0.45) | HRH3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14300800 | 0.75 | GRM5 (0.40) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7061476 | 0.74 | HRH3 (0.71) | HRH3 | |
| SCHEMBL506979 | 0.74 | HRH3 (0.71) | HRH3 | |
| SCHEMBL6496199 | 0.73 | SLC6A2 (0.66) | HRH3SLC6A2SLC6A4SLC6A3MGLL | |
| SCHEMBL932789 | 0.73 | HRH3 (0.44) | HRH3SLC6A2SLC6A4SLC6A3MGLL | |
| SCHEMBL593140 | 0.73 | KMT2A (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114873-B2 | 1,4-disubstituted naphthalenes as inhibitors of p38 map kinase | ARQULE, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114873-B2 | 1,4-disubstituted naphthalenes as inhibitors of p38 map kinase | ARQULE, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114873-B2 | 1,4-disubstituted naphthalenes as inhibitors of p38 map kinase | ARQULE, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100311754-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | ARQULE, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311754-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | ARQULE, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311754-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | ARQULE, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7829560-B2 | 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase | ARQULE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829560-B2 | 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase | ARQULE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829560-B2 | 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase | ARQULE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080032967-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | ARQULE, INC. | 2008-02-07 | — | — | US | disclosed |
| US-20080032967-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | ARQULE, INC. | 2008-02-07 | — | — | US | disclosed |
| US-20080032967-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | ARQULE, INC. | 2008-02-07 | — | — | US | disclosed |
| WO-2006010082-A1 | 1,4-DISUBSTITUTED NAPHTALENES AS INHIBITORS OF P38 MAP KINASE | ARQULE, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311754-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | MAPK1, MAPK7, MAP3K1 | HRH3 1484/4885SLC6A2 3822/4885SLC6A4 4386/4885 |
| US-20080032967-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | MAPK1, MAPK8, MAPK4 | HRH3 2036/4885SLC6A2 3495/4885SLC6A4 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.